OpGen (OPGN) Competitors $1.81 +0.14 (+8.40%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends OPGN vs. TTOO, ENZ, XGN, CCM, BNR, ATIP, TOI, RNLX, PMD, and BRTXShould you be buying OpGen stock or one of its competitors? The main competitors of OpGen include T2 Biosystems (TTOO), Enzo Biochem (ENZ), Exagen (XGN), Concord Medical Services (CCM), Burning Rock Biotech (BNR), ATI Physical Therapy (ATIP), Oncology Institute (TOI), Renalytix (RNLX), Psychemedics (PMD), and BioRestorative Therapies (BRTX). OpGen vs. T2 Biosystems Enzo Biochem Exagen Concord Medical Services Burning Rock Biotech ATI Physical Therapy Oncology Institute Renalytix Psychemedics BioRestorative Therapies OpGen (NASDAQ:OPGN) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking. Is OPGN or TTOO more profitable? T2 Biosystems has a net margin of -677.58% compared to OpGen's net margin of -1,140.36%. Company Net Margins Return on Equity Return on Assets OpGen-1,140.36% N/A -347.96% T2 Biosystems -677.58%N/A -155.89% Does the MarketBeat Community believe in OPGN or TTOO? T2 Biosystems received 105 more outperform votes than OpGen when rated by MarketBeat users. Likewise, 64.44% of users gave T2 Biosystems an outperform vote while only 54.14% of users gave OpGen an outperform vote. CompanyUnderperformOutperformOpGenOutperform Votes30154.14% Underperform Votes25545.86% T2 BiosystemsOutperform Votes40664.44% Underperform Votes22435.56% Which has more risk & volatility, OPGN or TTOO? OpGen has a beta of -0.65, indicating that its stock price is 165% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Do institutionals and insiders believe in OPGN or TTOO? 2.7% of OpGen shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 43.8% of OpGen shares are held by insiders. Comparatively, 0.1% of T2 Biosystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, OPGN or TTOO? OpGen has higher earnings, but lower revenue than T2 Biosystems. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpGen$2.67M5.65-$32.67MN/AN/AT2 Biosystems$7.19M2.07-$50.08MN/AN/A Do analysts recommend OPGN or TTOO? T2 Biosystems has a consensus price target of $5.00, indicating a potential upside of 487.61%. Given T2 Biosystems' higher probable upside, analysts plainly believe T2 Biosystems is more favorable than OpGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OpGen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AT2 Biosystems 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor OPGN or TTOO? In the previous week, OpGen had 1 more articles in the media than T2 Biosystems. MarketBeat recorded 1 mentions for OpGen and 0 mentions for T2 Biosystems. OpGen's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score. Company Overall Sentiment OpGen Neutral T2 Biosystems Neutral SummaryT2 Biosystems beats OpGen on 8 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get OpGen News Delivered to You Automatically Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPGN vs. The Competition Export to ExcelMetricOpGenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.10M$2.56B$5.39B$8.53BDividend YieldN/A1.69%5.13%4.14%P/E RatioN/A28.98114.3715.09Price / Sales5.65190.991,489.5696.92Price / CashN/A507.8339.6734.07Price / Book-0.164.414.665.02Net Income-$32.67M-$31.39M$119.06M$225.46M7 Day Performance9.55%1.36%0.80%0.37%1 Month Performance0.98%-1.44%5.65%3.57%1 Year Performance-72.24%35.68%36.75%29.43% OpGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPGNOpGenN/A$1.81+8.4%N/A-72.0%$15.10M$2.67M0.00100Analyst ForecastNews CoverageGap UpTTOOT2 Biosystems1.8145 of 5 stars$0.85-3.4%$5.00+487.6%-85.7%$15.31M$7.19M0.00180ENZEnzo Biochem0.5822 of 5 stars$1.13-1.7%N/A-15.7%$59.03M$31.91M0.00520Dividend AnnouncementAnalyst ForecastNews CoverageXGNExagen4.1971 of 5 stars$2.57+5.8%$7.00+172.4%+48.6%$42.25M$52.55M-2.65220High Trading VolumeCCMConcord Medical Services1.6687 of 5 stars$7.89+2.2%N/AN/A$34.26M$75.69M0.00970Analyst ForecastShort Interest ↓News CoverageBNRBurning Rock Biotech0.7289 of 5 stars$2.71-3.6%N/A-70.3%$27.75M$75.70M-0.561,390Gap DownATIPATI Physical Therapy1.6517 of 5 stars$5.63+4.6%N/A-19.3%$24.77M$699.02M-0.415,600Upcoming EarningsShort Interest ↓News CoverageTOIOncology Institute2.3103 of 5 stars$0.30-3.2%$2.50+733.6%-85.7%$22.64M$324.24M-0.38660Gap DownRNLXRenalytix1.2397 of 5 stars$0.21+5.7%$3.00+1,348.6%-79.7%$17.18M$2.29M-0.53100Gap UpPMDPsychemedicsN/A$2.32-0.4%N/A-6.5%$13.67M$20.79M-2.97140High Trading VolumeBRTXBioRestorative Therapies4.0457 of 5 stars$1.58+1.3%$18.00+1,039.2%-12.2%$10.80M$174,100.00-0.777Short Interest ↓Positive News Related Companies and Tools Related Companies TTOO Competitors ENZ Competitors XGN Competitors CCM Competitors BNR Competitors ATIP Competitors TOI Competitors RNLX Competitors PMD Competitors BRTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OPGN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
